Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2

J. Do Carmo Silva, S. Vesely, H. Luksanova, R. Prusa, M. Babjuk

. 2021 ; 43 (1) : 197-207. [pub] -

Language English Country Netherlands

Document type Journal Article

BACKGROUND: The role of isoforms of prostate specific antigen (PSA) and other kallikrein-related markers in early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is not well known and serum PSA is currently used in preoperative risk nomograms. OBJECTIVE: The aim of this research was to study pre- and early postoperative levels of important PSA isoforms and human kallikrein-2 to determine their ability to predict BCR and identify disease persistence (DP). METHODS: This study included 128 consecutive patients who underwent RP for clinically localized prostate cancer. PSA, fPSA, %fPSA, [-2]proPSA, PHI and hK2 were measured preoperatively, at 1 and 3 months after RP. We determined the ability of these markers to predict BCR and identify DP. RESULTS: The DP and BCR rate were 11.7%and 20.3%respectively and the median follow up was 64 months (range 3-76 months). Preoperatively, the independent predictors of BCR were PSA (p-value 0.029), [-2]proPSA (p-value 0.002) and PHI (p-value 0.0003). Post-RP, PSA was the single marker correlating with BCR, both at one (p-value 0.0047) and 3 months (p-value 0.0004). PSA, fPSA, [-2]proPSA and PHI significantly correlated to DP at 1 and 3 months post-RP (p-value <  0.05), although PSA had the most significant existing correlation (p-value <  0.0001). CONCLUSIONS: [-2]proPSA and PHI are preoperative predictors of BCR and DP that outperform the currently used serum PSA. At the early postoperative period there is no additional benefit of the other markers tested.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026317
003      
CZ-PrNML
005      
20211026133010.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/TUB-211509 $2 doi
035    __
$a (PubMed)34486998
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Do Carmo Silva, Joana $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
245    10
$a Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2 / $c J. Do Carmo Silva, S. Vesely, H. Luksanova, R. Prusa, M. Babjuk
520    9_
$a BACKGROUND: The role of isoforms of prostate specific antigen (PSA) and other kallikrein-related markers in early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is not well known and serum PSA is currently used in preoperative risk nomograms. OBJECTIVE: The aim of this research was to study pre- and early postoperative levels of important PSA isoforms and human kallikrein-2 to determine their ability to predict BCR and identify disease persistence (DP). METHODS: This study included 128 consecutive patients who underwent RP for clinically localized prostate cancer. PSA, fPSA, %fPSA, [-2]proPSA, PHI and hK2 were measured preoperatively, at 1 and 3 months after RP. We determined the ability of these markers to predict BCR and identify DP. RESULTS: The DP and BCR rate were 11.7%and 20.3%respectively and the median follow up was 64 months (range 3-76 months). Preoperatively, the independent predictors of BCR were PSA (p-value 0.029), [-2]proPSA (p-value 0.002) and PHI (p-value 0.0003). Post-RP, PSA was the single marker correlating with BCR, both at one (p-value 0.0047) and 3 months (p-value 0.0004). PSA, fPSA, [-2]proPSA and PHI significantly correlated to DP at 1 and 3 months post-RP (p-value <  0.05), although PSA had the most significant existing correlation (p-value <  0.0001). CONCLUSIONS: [-2]proPSA and PHI are preoperative predictors of BCR and DP that outperform the currently used serum PSA. At the early postoperative period there is no additional benefit of the other markers tested.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a lokální recidiva nádoru $x krev $x diagnóza $x genetika $7 D009364
650    _2
$a nomogramy $7 D049451
650    _2
$a pooperační období $7 D011184
650    _2
$a prostata $x patologie $x chirurgie $7 D011467
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a prostatektomie $7 D011468
650    _2
$a nádory prostaty $x krev $x diagnóza $x genetika $x chirurgie $7 D011471
650    _2
$a protein - isoformy $x krev $x genetika $7 D020033
650    _2
$a tkáňové kalikreiny $x krev $7 D020840
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vesely, Stepan $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
700    1_
$a Luksanova, Hana $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
700    1_
$a Prusa, Richard $u Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic
700    1_
$a Babjuk, Marko $u Department of Urology, Second Faculty of Medicine of Charles University, University Hospital Motol, Prague, Czech Republic $u Department of Urology, Medical University of Vienna, Austria
773    0_
$w MED00008757 $t Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine $x 1423-0380 $g Roč. 43, č. 1 (2021), s. 197-207
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34486998 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133016 $b ABA008
999    __
$a ok $b bmc $g 1715133 $s 1146824
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 43 $c 1 $d 197-207 $e - $i 1423-0380 $m Tumor biology $n Tumor Biol $x MED00008757
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...